AI-generated analysis. Always verify with the original filing.
Damora Therapeutics, Inc. appointed Jennifer Jarrett as President and Chief Executive Officer effective March 30, 2026, succeeding Sherwin Sattarzadeh who continues as COO, and appointed Michael Landsittel and Cameron Turtle as Class III directors effective March 23, 2026. Three directors resigned, Peter Harwin became Board Chair, and Garrett Winslow received a new offer letter as General Counsel.
Event Type
Disclosure
Mandatory
Variant
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executi
Regulation FD Disclosure. On March 23, 2026, the Company issued a press release announcing the CEO and director appointments, a copy of which press release is f
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Document 10.1 Offer Letter, dated February 25, 2026, between Damora Therapeutics,
Jennifer Jarrett
Effective: 2026-03-30
Sherwin Sattarzadeh
Effective: 2026-03-30
Amit Munshi
Effective: 2026-03-23
not due to disagreements
Carl Goldfischer
Effective: 2026-03-23
not due to disagreements
Jayson Dallas
Effective: 2026-03-23
not due to disagreements
Michael Landsittel
Effective: 2026-03-23
Cameron Turtle
Effective: 2026-03-23
Peter Harwin
Effective: 2026-03-23
Garrett Winslow
Effective: 2026-03-20